Artimplant and Tiller signs an agreement

Artimplant AB (publ) and Tiller International Capital have today entered into an
agreement regarding a Sales, Marketing and Distribution Agreement which will
gives Tiller the exclusive right to sell, market and distribute all Artimplant´s
products outside Europe and non exclusively within Europe.

The detailed operational procedures are expected to be completed within the next
four weeks.

The current sales efforts of Artimplant in the USA will be coordinated with
Tiller to support both new and existing customers in the best way.

Tiller works extensively with Healthcare groups such as Catholic Healthcare on a
Global basis to provide the best possible facilities and treatment for patients.
Catholic Healthcare treats 30,000,000 patients a year in its more than 600
hospitals.

“I am very happy and satisfied to enter into this Agreement with Tiller. The
Agreement gives Artimplant a good platform to expand the business and also a
partner who has a lot of experience from both the US and Global markets”, says
Kjell Thörnbring, CEO Artimplant.

Anthony N. Georgiou, Chairman of Tiller says, “With our network in the
Healthcare systems and the partners we are cooperating with, we see a huge
potential in Artimplant´s products and are looking forward to a very fruitful
future together”.

Västra Frölunda, May 30, 2013
Kjell Thörnbring
CEO

For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 119 025

Further information is available at www.artimplant.com where you can also
subscribe to future press releases; www.artimplant.com/investors-media/subscribe
-to-press-releases.html

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedics. We restore health through the development, production and marketing
of degradable implants that regenerate body functions and improve quality of
life. Our products, made from Artelon®, meet unmet clinical needs and are
marketed in a growing number of therapy areas. Artimplant produces implants for
treatment of osteoarthritis in hands and feet as well as shoulder and other soft
tissue injuries.

Artimplant is a public company, listed on NASDAQ OMX Stockholm in the Small Cap
segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting on the Company's business, including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information that Artimplant will make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on May 30, 2013 at 11 am (Swedish time).